← Back to Clinical Trials
Recruiting NCT04662918

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Trial Parameters

Condition GastroIntestinal Bleeding
Sponsor Xingshun Qi
Study Type OBSERVATIONAL
Phase N/A
Enrollment 3,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-01-01
Completion 2025-12

Brief Summary

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

Eligibility Criteria

Inclusion Criteria: 1. Patients with liver cirrhosis; 2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia; 3. Adults (age≥18 years old). Exclusion Criteria: 1. Components of Child-Pugh, MELD, and CAGIB scores are not available; 2. In-hospital outcomes are not evaluable.

Related Trials